Algernon Pharmaceuticals (AGNPF) News Today → Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad) Free AGNPF Stock Alerts $0.11 0.00 (0.00%) (As of 05/20/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 12, 2024 | americanbankingnews.comAlgernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Short Interest UpdateApril 24, 2024 | globenewswire.comAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024April 11, 2024 | globenewswire.comAlgernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024April 3, 2024 | msn.comDMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial DesignApril 1, 2024 | globenewswire.comAlgernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead AssetMarch 28, 2024 | finance.yahoo.comAlgernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough TreatmentMarch 27, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - AGNMarch 27, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - AGNMarch 27, 2024 | proactiveinvestors.comAlgernon Pharmaceuticals closes $2M acquisition of its chronic cough research program by SeyltxMarch 27, 2024 | globenewswire.comAlgernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity PositionJanuary 31, 2024 | finance.yahoo.comAlgernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKDJanuary 11, 2024 | finance.yahoo.comAlgernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary FibrosisDecember 27, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces Increase to Private PlacementNovember 30, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLDNovember 22, 2023 | msn.comSeyltx acquires Algernon's chronic cough research program for $2M and 20% stakeNovember 22, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity PositionNovember 12, 2023 | uk.finance.yahoo.comAlgernon Pharmaceuticals Inc. (AGN.CN)November 8, 2023 | msn.comAlgernon gets Japanese patent notice of allowance for treatment of NASH with RepirinastNovember 8, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with RepirinastSeptember 9, 2023 | investing.comAlgernon Pharmaceuticals Inc Class A (AGN)September 6, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASHAugust 8, 2023 | benzinga.comDMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 StudyAugust 8, 2023 | finance.yahoo.comAlgernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke StudyJuly 14, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory AgreementJune 27, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development ProgramJune 6, 2023 | finance.yahoo.comAlgernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough ConferenceJune 5, 2023 | finance.yahoo.comAlgernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose studyJune 5, 2023 | proactiveinvestors.comAlgernon Pharmaceuticals subsidiary completes DMT escalating dose studyJune 5, 2023 | finance.yahoo.comAlgernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI StudiesMay 31, 2023 | proactiveinvestors.comAlgernon Pharmaceuticals receives Notice of Allowance from Japanese Patent Office for RepirinastMay 31, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKDMay 5, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces Closing of Rights OfferingApril 27, 2023 | finance.yahoo.comIIROC Trading Halt - AGN.RTApril 20, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and TimeApril 18, 2023 | finance.yahoo.comAlgernon Pharmaceuticals receives notice of allowance for US patent for drug Repirinast and NASHApril 17, 2023 | proactiveinvestors.comAlgernon Pharma receives Notice of Allowance from US Patent and Trademark Office for RepirinastApril 17, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent ApplicationApril 5, 2023 | finance.yahoo.comAlgernon NeuroScience reports successful second cohort dosing in DMT clinical studyApril 4, 2023 | benzinga.comIntravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI TreatmentApril 4, 2023 | proactiveinvestors.comAlgernon Pharmaceuticals announces successful dosing of second cohort in Phase 1 DMT clinical studyApril 4, 2023 | finance.yahoo.comAlgernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical StudyApril 3, 2023 | proactiveinvestors.comAlgernon Pharma says wholly-owned subsidiary's Reg A+ offering gets US SEC qualificationApril 3, 2023 | finanznachrichten.deAlgernon Pharmaceuticals: Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10MApril 3, 2023 | finance.yahoo.comAlgernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10MMarch 2, 2023 | proactiveinvestors.comFormer NFL neurologist joins Algernon's program using DMT to treat traumatic brain injuryMarch 2, 2023 | finance.yahoo.comAlgernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory BoardMarch 1, 2023 | msn.comAlgernon Pharmaceuticals Goes 4:1 In Forward Share Split After Announcing New TBI ProgramMarch 1, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces 4 for 1 Forward Share SplitFebruary 21, 2023 | benzinga.comDeveloping Psychedelic Treatments For Traumatic Brain Injury: Algernon Launches New ProgramFebruary 21, 2023 | proactiveinvestors.comAlgernon Pharmaceuticals says unit initiates traumatic brain injury research program with DMT; appoints global TBI expert as advisor Get Algernon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGNPF and its competitors with MarketBeat's FREE daily newsletter. Email Address What President Biden's new law means for investors (Ad)What's Got Musk, Bezos, and Gates So Excited? Billionaires are plowing millions of dollars into a new technology that early estimates say could generate more wealth than A.I. – and determine the future of companies like Microsoft. The problem? Most investors have no idea it's happening, or how to profit on it. This expert just went public with all the details, including which stocks to jump on immediately. AGNPF Media Mentions By Week AGNPF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGNPF News Sentiment▼0.000.42▲Average Medical News Sentiment AGNPF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGNPF Articles This Week▼00▲AGNPF Articles Average Week Get Algernon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGNPF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALK-Abelló A/S News Today Alpha Tau Medical News Today Arno Therapeutics News Today Artelo Biosciences News Today Ascletis Pharma News Today Awakn Life Sciences News Today AXIM Biotechnologies News Today BerGenBio ASA News Today BriaCell Therapeutics News Today Clinuvel Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:AGNPF) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe #1 Crypto for AIWeiss Ratings**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Algernon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
